AP765A - Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. - Google Patents

Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. Download PDF

Info

Publication number: AP765A
Authority: AP; ARIPO
Prior art keywords: ziprasidone mesylate; ziprasidone; crystals; mesylate; dihydrate
Prior art date: 1996-05-07

Application number

APAP/P/1997/000976A

Other languages

English (en)

Other versions

AP9700976A0 (en

Inventor

Frank Robert Busch

Carol Anne Rose

Russell James Shine

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-07

Filing date

1997-04-30

Publication date

1999-09-17

1997-04-30 Application filed by Pfizer filed Critical Pfizer

1997-07-31 Publication of AP9700976A0 publication Critical patent/AP9700976A0/xx

1999-09-17 Application granted granted Critical

1999-09-17 Publication of AP765A publication Critical patent/AP765A/en

Links

WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 title description 33
229960004487 ziprasidone mesylate Drugs 0.000 title description 29
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
229960003638 dopamine Drugs 0.000 title 1
UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical class O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 claims abstract description 14
208000028017 Psychotic disease Diseases 0.000 claims abstract description 11
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical class C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims abstract description 10
238000000034 method Methods 0.000 claims abstract description 9
239000008194 pharmaceutical composition Chemical class 0.000 claims abstract description 6
239000013078 crystal Substances 0.000 claims description 39
201000000980 schizophrenia Diseases 0.000 claims description 5
208000019901 Anxiety disease Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
238000010255 intramuscular injection Methods 0.000 claims description 3
239000007927 intramuscular injection Substances 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 21
239000002002 slurry Substances 0.000 description 19
238000003756 stirring Methods 0.000 description 17
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
239000000243 solution Substances 0.000 description 13
238000000634 powder X-ray diffraction Methods 0.000 description 11
229940098779 methanesulfonic acid Drugs 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
238000010992 reflux Methods 0.000 description 10
150000004683 dihydrates Chemical class 0.000 description 9
238000001228 spectrum Methods 0.000 description 8
239000008227 sterile water for injection Substances 0.000 description 8
LOQSYPGSAZUDJZ-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 LOQSYPGSAZUDJZ-UHFFFAOYSA-N 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000010438 heat treatment Methods 0.000 description 6
239000012458 free base Substances 0.000 description 5
239000000523 sample Substances 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
229960000607 ziprasidone Drugs 0.000 description 4
ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
-1 Ziprasidone dihydrate Chemical class 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
239000011888 foil Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
125000004193 piperazinyl group Chemical group 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000010583 slow cooling Methods 0.000 description 3
150000004684 trihydrates Chemical class 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000004744 fabric Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
LKGCPYOBWLSCTK-UHFFFAOYSA-N methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O LKGCPYOBWLSCTK-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000008719 thickening Effects 0.000 description 2
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Saccharide Compounds (AREA)

APAP/P/1997/000976A 1996-05-07 1997-04-30 Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. AP765A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1675796P	1996-05-07	1996-05-07

Publications (2)

Publication Number	Publication Date
AP9700976A0 AP9700976A0 (en)	1997-07-31
AP765A true AP765A (en)	1999-09-17

Family

ID=21778804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1997/000976A AP765A (en)	1996-05-07	1997-04-30	Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.

Country Status (40)

Country	Link
US (1)	US6245765B1 (fr)
EP (1)	EP0918772B1 (fr)
JP (1)	JP3494659B2 (fr)
KR (1)	KR100333215B1 (fr)
CN (1)	CN1091769C (fr)
AP (1)	AP765A (fr)
AR (1)	AR007004A1 (fr)
AT (1)	ATE278689T1 (fr)
AU (1)	AU731267B2 (fr)
BG (1)	BG63544B1 (fr)
BR (1)	BR9709889A (fr)
CA (1)	CA2252898C (fr)
CO (1)	CO4940466A1 (fr)
CZ (1)	CZ289215B6 (fr)
DE (1)	DE69731094T2 (fr)
DK (1)	DK0918772T3 (fr)
DZ (1)	DZ2222A1 (fr)
EA (1)	EA001190B1 (fr)
EG (1)	EG24076A (fr)
ES (1)	ES2229342T3 (fr)
GT (1)	GT199700052A (fr)
HR (1)	HRP970236B1 (fr)
ID (1)	ID16867A (fr)
IL (1)	IL126591A (fr)
IS (1)	IS2080B (fr)
MA (1)	MA24171A1 (fr)
MY (1)	MY119997A (fr)
NO (1)	NO312514B1 (fr)
NZ (1)	NZ332218A (fr)
OA (1)	OA10909A (fr)
PL (1)	PL188330B1 (fr)
PT (1)	PT918772E (fr)
SI (1)	SI0918772T1 (fr)
SK (1)	SK282837B6 (fr)
TN (1)	TNSN97074A1 (fr)
TR (1)	TR199802240T2 (fr)
TW (1)	TW491847B (fr)
UA (1)	UA46840C2 (fr)
WO (1)	WO1997042191A1 (fr)
ZA (1)	ZA973876B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
UA57734C2 (uk)	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1698338B1 (fr) *	2000-06-02	2008-04-09	Pfizer Products Inc.	S-methyl-dihydro-ziprasidone pour traiter la schizophrénie
US20040048876A1 (en) *	2002-02-20	2004-03-11	Pfizer Inc.	Ziprasidone composition and synthetic controls
UY27668A1 (es)	2002-02-20	2003-10-31	Pfizer Prod Inc	Composición de ziprasidona y controles sintéticos
EP1633400A2 (fr)	2003-05-16	2006-03-15	Pfizer Products Inc.	Combinaisons therapeutiques d'antipsychotiques atypiques avec des modulateurs de l'acide 4-aminobutanoique et/ou des medicaments anticonvulsivants
EP1546146A1 (fr) *	2003-06-03	2005-06-29	Teva Pharmaceutical Industries Limited	Formes polymorphes de ziprasidone chlorhydrate et procedes pour leur elaboration
WO2005040160A2 (fr)	2003-10-24	2005-05-06	Teva Pharmaceutical Industries Ltd.	Procedes de preparation de ziprasidone
MXPA06013163A (es) *	2004-05-11	2007-02-13	Pfizer Prod Inc	Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
CA2467538C (fr)	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production
CA2471219A1 (fr)	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Preparation amelioree d'une forme anhydre du chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one (chlorhydrate de ziprasidone)
US7777037B2 (en) *	2004-10-27	2010-08-17	Dr. Reddy's Laboratories Limited	Ziprasidone process
US7910577B2 (en) *	2004-11-16	2011-03-22	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
EP1742943A1 (fr) *	2005-02-11	2007-01-17	Teva Pharmaceutical Industries Ltd	Procede de preparation de ziprasidone mesylate
CA2593497A1 (fr) *	2005-02-11	2006-08-17	Judith Aronhime	Ziprasidone mesylate amorphe
US20080254114A1 (en) *	2005-03-03	2008-10-16	Elan Corporation Plc	Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it)	2005-03-07	2006-09-08	Dipharma Spa	Forma solida di ziprasidone cloridrato
CA2500667C (fr)	2005-03-11	2013-01-15	Apotex Pharmachem Inc.	Synthese de sels d'addition acide de ziprasidone et de produits intermediaires connexes au moyen de reactions solide-gaz
WO2006098834A2 (fr) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Formes cristallines de mesylate de ziprasidone
EP1858892A1 (fr) *	2005-03-14	2007-11-28	Teva Pharmaceutical Industries Ltd	Mesylate de ziprasidone anhydre et son procede de preparation
ITMI20052216A1 (it) *	2005-11-18	2007-05-19	Dipharma Spa	Procedimento per la preparazione di ziprasidone
WO2008143960A1 (fr) *	2007-05-18	2008-11-27	Scidose Llc	Formulations de ziprasidone
WO2009156889A1 (fr) *	2008-06-25	2009-12-30	Pfizer Inc.	Composés diaryle et leurs utilisations
WO2012053654A1 (fr) *	2010-10-18	2012-04-26	Dainippon Sumitomo Pharma Co., Ltd.	Formulation à libération prolongée pour injection
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (fr) *	1992-08-26	1994-03-02	Pfizer Inc.	Procédé de préparation de dérivés aryl pipérazinyl-hétérocycliques
WO1995000510A1 (fr) *	1993-06-28	1995-01-05	Pfizer Inc.	Procedes et intermediaires pour la preparation de 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX173362B (es) *	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
ATE236902T1 (de)	1996-05-07	2003-04-15	Pfizer	Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist

1997
- 1997-04-01 TW TW086104173A patent/TW491847B/zh not_active IP Right Cessation
- 1997-04-10 AT AT97914520T patent/ATE278689T1/de not_active IP Right Cessation
- 1997-04-10 IL IL12659197A patent/IL126591A/en not_active IP Right Cessation
- 1997-04-10 DE DE69731094T patent/DE69731094T2/de not_active Expired - Lifetime
- 1997-04-10 TR TR1998/02240T patent/TR199802240T2/xx unknown
- 1997-04-10 CN CN97194244A patent/CN1091769C/zh not_active Expired - Fee Related
- 1997-04-10 SI SI9730676T patent/SI0918772T1/xx unknown
- 1997-04-10 KR KR1019980708960A patent/KR100333215B1/ko not_active Expired - Fee Related
- 1997-04-10 AU AU21747/97A patent/AU731267B2/en not_active Ceased
- 1997-04-10 NZ NZ332218A patent/NZ332218A/en unknown
- 1997-04-10 EA EA199800912A patent/EA001190B1/ru not_active IP Right Cessation
- 1997-04-10 CA CA002252898A patent/CA2252898C/fr not_active Expired - Lifetime
- 1997-04-10 CZ CZ19983493A patent/CZ289215B6/cs not_active IP Right Cessation
- 1997-04-10 PL PL97329884A patent/PL188330B1/pl unknown
- 1997-04-10 US US09/180,455 patent/US6245765B1/en not_active Expired - Lifetime
- 1997-04-10 JP JP53967297A patent/JP3494659B2/ja not_active Expired - Lifetime
- 1997-04-10 ES ES97914520T patent/ES2229342T3/es not_active Expired - Lifetime
- 1997-04-10 DK DK97914520T patent/DK0918772T3/da active
- 1997-04-10 EP EP97914520A patent/EP0918772B1/fr not_active Expired - Lifetime
- 1997-04-10 WO PCT/IB1997/000393 patent/WO1997042191A1/fr not_active Ceased
- 1997-04-10 SK SK1508-98A patent/SK282837B6/sk not_active IP Right Cessation
- 1997-04-10 UA UA98115905A patent/UA46840C2/uk unknown
- 1997-04-10 BR BR9709889A patent/BR9709889A/pt not_active Application Discontinuation
- 1997-04-10 PT PT97914520T patent/PT918772E/pt unknown
- 1997-04-29 CO CO97022872A patent/CO4940466A1/es unknown
- 1997-04-29 GT GT199700052A patent/GT199700052A/es unknown
- 1997-04-30 AP APAP/P/1997/000976A patent/AP765A/en active
- 1997-05-04 EG EG37997A patent/EG24076A/xx active
- 1997-05-05 ID IDP971492A patent/ID16867A/id unknown
- 1997-05-05 AR ARP970101856A patent/AR007004A1/es unknown
- 1997-05-06 TN TNTNSN97074A patent/TNSN97074A1/fr unknown
- 1997-05-06 DZ DZ970069A patent/DZ2222A1/fr active
- 1997-05-06 MY MYPI97001989A patent/MY119997A/en unknown
- 1997-05-06 MA MA24595A patent/MA24171A1/fr unknown
- 1997-05-06 ZA ZA973876A patent/ZA973876B/xx unknown
- 1997-05-07 HR HR970236A patent/HRP970236B1/xx not_active IP Right Cessation
1998
- 1998-10-20 IS IS4874A patent/IS2080B/is unknown
- 1998-10-30 OA OA9800206A patent/OA10909A/fr unknown
- 1998-11-03 BG BG102892A patent/BG63544B1/bg unknown
- 1998-11-06 NO NO19985194A patent/NO312514B1/no unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (fr) *	1992-08-26	1994-03-02	Pfizer Inc.	Procédé de préparation de dérivés aryl pipérazinyl-hétérocycliques
WO1995000510A1 (fr) *	1993-06-28	1995-01-05	Pfizer Inc.	Procedes et intermediaires pour la preparation de 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number	Publication date
IS2080B (is)	2006-02-15
DE69731094T2 (de)	2006-02-23
CN1216991A (zh)	1999-05-19
CZ289215B6 (cs)	2001-12-12
KR20000010824A (ko)	2000-02-25
TW491847B (en)	2002-06-21
JP3494659B2 (ja)	2004-02-09
IS4874A (is)	1998-10-20
TNSN97074A1 (fr)	2005-03-15
AP9700976A0 (en)	1997-07-31
HK1017892A1 (en)	1999-12-03
AU731267B2 (en)	2001-03-29
MA24171A1 (fr)	1997-12-31
BR9709889A (pt)	1999-08-10
CA2252898A1 (fr)	1997-11-13
BG63544B1 (bg)	2002-04-30
TR199802240T2 (fr)	1999-02-22
PT918772E (pt)	2004-12-31
NO985194D0 (no)	1998-11-06
UA46840C2 (uk)	2002-06-17
EP0918772B1 (fr)	2004-10-06
DK0918772T3 (da)	2005-01-10
CN1091769C (zh)	2002-10-02
AU2174797A (en)	1997-11-26
CZ349398A3 (cs)	1999-09-15
WO1997042191A1 (fr)	1997-11-13
EA001190B1 (ru)	2000-12-25
DE69731094D1 (de)	2004-11-11
ID16867A (id)	1997-11-20
PL188330B1 (pl)	2005-01-31
KR100333215B1 (ko)	2002-06-20
ATE278689T1 (de)	2004-10-15
SI0918772T1 (en)	2005-02-28
EG24076A (en)	2008-05-11
HRP970236A2 (en)	1998-06-30
GT199700052A (es)	2001-08-29
NZ332218A (en)	2005-02-25
AR007004A1 (es)	1999-10-13
SK150898A3 (en)	2000-02-14
SK282837B6 (sk)	2002-12-03
DZ2222A1 (fr)	2002-12-03
NO312514B1 (no)	2002-05-21
HRP970236B1 (en)	2002-12-31
PL329884A1 (en)	1999-04-12
ES2229342T3 (es)	2005-04-16
NO985194L (no)	1998-11-06
IL126591A (en)	2001-11-25
IL126591A0 (en)	1999-08-17
OA10909A (en)	2001-10-26
US6245765B1 (en)	2001-06-12
ZA973876B (en)	1998-11-06
EA199800912A1 (ru)	1999-04-29
JPH11509867A (ja)	1999-08-31
BG102892A (en)	1999-09-30
CO4940466A1 (es)	2000-07-24
EP0918772A1 (fr)	1999-06-02
MY119997A (en)	2005-08-30
CA2252898C (fr)	2003-04-08

Publication	Publication Date	Title
AP765A (en)	1999-09-17	Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.
AP838A (en)	2000-05-03	Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
NZ508304A (en)	2001-05-25	Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
MXPA98009242A (en)	1999-09-01	Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-
HUP9902404A2 (hu)	2000-02-28	5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása